TA
Therapeutic Areas
Caribou Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Vispacabtagene regedleucel (vispa-cel, CB-010) | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (r/r B-NHL) | Phase 1 |
| CB-011 | Relapsed/Refractory Multiple Myeloma (r/r MM) | Phase 1 |
| CB-012 | Acute Myeloid Leukemia (AML) | Preclinical |
| CB-020 | Solid Tumors | Preclinical |
Leadership Team at Caribou Biosciences
RH
Rachel Haurwitz, PhD
President and Chief Executive Officer
TK
Tim Kelly
Chief Technology Officer
RK
Ruhi Khan
Chief Business Officer
BM
Barbara McClung, JD
Chief Legal Officer and Corporate Secretary
SR
Sri Ryali
Chief Financial Officer
RZ
Reigin Zawadzki
Chief People Officer
JD
Jennifer Doudna, PhD
Co-founder, Scientific Advisory Board